OMEROS CORP (OMER) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -72.82M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 62.60M USD | Research and Development Expense |
| Selling, general and administration | 47.26M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-72.82M | (m) | (m) | $62.60M | $47.26M | (m) |
| 2026-03-31 | $-105.25M | (m) | (m) | $70.81M | $43.75M | (m) |
| 2025-12-31 | $-122.80M | (m) | (m) | $81.30M | $41.50M | (m) |
| 2025-09-30 | $-129.38M | (m) | (m) | $85.17M | $44.20M | (m) |
| 2025-06-30 | $-138.39M | (m) | (m) | $93.26M | $45.13M | (m) |
| 2025-03-31 | $-165.19M | (m) | (m) | $116.60M | $48.59M | (m) |
| 2024-12-31 | $-169.26M | (m) | (m) | $119.52M | $49.73M | (m) |
| 2024-09-30 | $-173.36M | (m) | (m) | $125.09M | $48.27M | (m) |
| 2024-06-30 | $-186.11M | (m) | (m) | $132.74M | $53.37M | (m) |
| 2024-03-31 | $-167.85M | (m) | (m) | $117.03M | $50.82M | (m) |
| 2023-12-31 | $-164.53M | (m) | (m) | $114.87M | $49.66M | (m) |
| 2023-09-30 | $-164.90M | (m) | (m) | $112.53M | (m) | (m) |
| 2023-06-30 | $-167.52M | (m) | (m) | $119.37M | (m) | (m) |
| 2023-03-31 | $-164.06M | (m) | (m) | $113.24M | (m) | (m) |
| 2022-12-31 | $-163.39M | (m) | (m) | $112.72M | (m) | (m) |
| 2022-09-30 | $-166.14M | (m) | (m) | $116.50M | (m) | (m) |
| 2022-06-30 | $-155.20M | (m) | (m) | $103.75M | (m) | (m) |
| 2022-03-31 | $-163.37M | (m) | (m) | $110.36M | (m) | (m) |
| 2021-12-31 | $-173.62M | (m) | (m) | $118.78M | (m) | (m) |
| 2021-09-30 | $-106.70M | $90.52M | $1.02M | $117.82M | (m) | -117.87% |
| 2021-06-30 | $-113.87M | $86.63M | $1.09M | $122.08M | (m) | -131.44% |
| 2021-03-31 | $-117.54M | $71.34M | $898.00K | $115.26M | (m) | -164.76% |
| 2020-12-31 | $-110.60M | $73.81M | $902.00K | $110.82M | (m) | -149.84% |
| 2020-09-30 | $-100.51M | $96.60M | $1.22M | $124.95M | (m) | -104.05% |
| 2020-06-30 | $-86.18M | $100.34M | $1.09M | $117.38M | (m) | -85.89% |
| 2020-03-31 | $-67.84M | $113.56M | $1.00M | $112.35M | (m) | -59.74% |
| 2019-12-31 | $-63.38M | $111.81M | $865.00K | $109.70M | (m) | -56.69% |
| 2019-09-30 | $-58.15M | $100.41M | $621.00K | $94.55M | (m) | -57.92% |
| 2019-06-30 | $-82.50M | $75.16M | $379.00K | $97.67M | (m) | -109.77% |
| 2019-03-31 | $-103.77M | $50.06M | $440.00K | $97.97M | (m) | -207.30% |
| 2018-12-31 | $-112.22M | $29.87M | $512.00K | $89.86M | (m) | -375.73% |
| 2018-09-30 | $-107.87M | $21.61M | (m) | $79.80M | (m) | -499.13% |
| 2018-06-30 | $-77.53M | (m) | (m) | $67.77M | (m) | (m) |
| 2018-03-31 | $-58.86M | (m) | (m) | $61.50M | (m) | (m) |
| 2017-12-31 | $-43.90M | $64.83M | (m) | $55.60M | (m) | -67.71% |
| 2017-09-30 | $-41.63M | $63.97M | (m) | $52.75M | (m) | -65.08% |
| 2017-06-30 | $-48.56M | $53.60M | (m) | $50.41M | (m) | -90.59% |
| 2017-03-31 | $-47.55M | $46.45M | (m) | $47.51M | (m) | -102.35% |
| 2016-12-31 | $-54.28M | $41.62M | (m) | $50.70M | (m) | -130.42% |
| 2016-09-30 | $-60.46M | $35.39M | (m) | $53.05M | (m) | -170.85% |
| 2016-06-30 | $-67.72M | $27.36M | (m) | $53.83M | (m) | -247.55% |
| 2016-03-31 | $-72.76M | $20.54M | (m) | $54.49M | (m) | -354.24% |
| 2015-12-31 | $-71.24M | $13.51M | (m) | $48.38M | (m) | -527.34% |
| 2015-09-30 | $-73.17M | $7.01M | (m) | $45.23M | (m) | -1043.24% |
| 2015-06-30 | $-71.00M | $3.97M | (m) | $43.74M | (m) | -1788.96% |
| 2015-03-31 | $-72.25M | $827.00K | (m) | $45.25M | (m) | -8736.88% |
| 2014-12-31 | $-70.01M | $539.00K | (m) | $47.95M | (m) | -12988.50% |
| 2014-09-30 | $-63.94M | $528.00K | (m) | $46.38M | (m) | -12108.90% |
| 2014-06-30 | $-60.24M | $510.00K | (m) | $44.03M | (m) | -11811.18% |
| 2014-03-31 | $-56.18M | $605.00K | (m) | $41.19M | (m) | -9285.95% |
| 2013-12-31 | $-50.52M | $1.60M | (m) | $36.30M | (m) | -3157.25% |
| 2013-09-30 | $-44.15M | $3.01M | (m) | $35.47M | (m) | -1464.73% |
| 2013-06-30 | $-43.75M | $4.24M | (m) | $33.81M | (m) | -1033.03% |
| 2013-03-31 | $-38.83M | $5.62M | (m) | $31.80M | (m) | -690.86% |
| 2012-12-31 | $-36.88M | $6.02M | (m) | $31.92M | (m) | -612.50% |
| 2012-09-30 | $-39.20M | $5.58M | (m) | $31.46M | (m) | -702.24% |
| 2012-06-30 | $-32.33M | $5.15M | (m) | $29.02M | (m) | -627.47% |
| 2012-03-31 | $-29.03M | $4.78M | (m) | $25.54M | (m) | -607.24% |
| 2011-12-31 | $-27.41M | $4.52M | (m) | $23.72M | (m) | -605.88% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-30.11M | $2.10M | (m) | $23.46M | (m) | -1430.21% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-20.76M | $1.44M | (m) | $16.93M | (m) | -1437.53% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |